MVA-SARS-2-S / German Center for Infection Research, University Medical Center Hamburg-Eppendorf - LARVOL DELTA

Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate (clinicaltrials.gov) - P1 | N=23 | Terminated | Sponsor: Hannover Medical School | Trial completion date: Apr 2024 ➔ Nov 2023 | Recruiting ➔ Terminated; cohort could not be recruited

Trial completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Hannover Medical School | Trial completion date: Oct 2023 ➔ Apr 2024 | Trial primary completion date: Feb 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

SARS-CoV-2 Spike Conformation Essentially Influences Vaccine Immunogenicity – Results from Two Clinical Phase I Trials of the Vector Vaccine Candidates MVA-SARS-2-S and MVA-SARS-2-ST (IDWeek 2023) - No abstract available

Clinical • P1 data • Infectious Disease • Novel Coronavirus Disease

Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice. (PubMed, Viruses) - "Thus, our results suggest that the chosen time intervals may not be suitable to observe potential differences in antigen-specific immunity when testing different prime-boost intervals with our candidate vaccines in the mouse model. Despite this, our data clearly showed that MVA-SARS-2-ST induced superior humoral immune responses relative to MVA-SARS-2-S after both immunization schedules."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD8

Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19 (clinicaltrials.gov) - P1 | N=43 | Completed | Sponsor: Universitätsklinikum Hamburg-Eppendorf | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19 (clinicaltrials.gov) - P1 | N=60 | Active, not recruiting | Sponsor: Universitätsklinikum Hamburg-Eppendorf | Trial primary completion date: Aug 2022 ➔ Nov 2022

Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19 (clinicaltrials.gov) - P1 | N=60 | Active, not recruiting | Sponsor: Universitätsklinikum Hamburg-Eppendorf | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease

Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19 (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Universitätsklinikum Hamburg-Eppendorf | Trial completion date: Mar 2022 ➔ Oct 2022 | Trial primary completion date: Mar 2022 ➔ Aug 2022

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Hannover Medical School | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Hannover Medical School

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19 (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Universitätsklinikum Hamburg-Eppendorf; Phase classification: P1/2 ➔ P1; N=240 ➔ 60

Clinical • Enrollment change • Phase classification • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19 (clinicaltrials.gov) - P1; N=30; Completed; Sponsor: Universitätsklinikum Hamburg-Eppendorf; Active, not recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • Novel Coronavirus Disease

Characterization of Individuals Interested in Participating in a Phase I SARS-CoV-2 Vaccine Trial. (PubMed, Vaccines (Basel)) - "From 20 May 2020, public announcements about a planned phase I trial of the vaccine candidate MVA-SARS-2-S against SARS-CoV-2 began, and interested individuals started contacting the study team via designated e-mail...Factors such as media coverage and the perception of a disease as an acute threat may influence the individual's choice to volunteer for a vaccine trial. Our data provide first important insights to better understand reasons to participate in such trials to facilitate trial implementation and recruitment."

Clinical • Journal • P1 data • Cognitive Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19 (clinicaltrials.gov) - P1; N=30; Active, not recruiting; Sponsor: Universitätsklinikum Hamburg-Eppendorf; Recruiting ➔ Active, not recruiting; Trial completion date: May 2021 ➔ Sep 2021; Trial primary completion date: May 2021 ➔ Sep 2021

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19 (clinicaltrials.gov) - P1/2; N=240; Recruiting; Sponsor: Universitätsklinikum Hamburg-Eppendorf; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. (PubMed, Proc Natl Acad Sci U S A) - "Prime-boost vaccination with MVA-SARS-2-S protected mice sensitized with a human ACE2-expressing adenovirus from SARS-CoV-2 infection. MVA-SARS-2-S is currently being investigated in a phase I clinical trial as aspirant for developing a safe and efficacious vaccine against COVID-19."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD8

Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19 (clinicaltrials.gov) - P1/2; N=240; Not yet recruiting; Sponsor: Universitätsklinikum Hamburg-Eppendorf

Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease

Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S Against COVID-19 (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: Universitätsklinikum Hamburg-Eppendorf; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease